The risk or severity of adverse effects can be increased when Tamsulosin is combined with Methyclothiazide. The therapeutic efficacy of Folic Acid can be decreased when used in combination with Semapimod. Prednisone may increase the hypokalemic activities of Cyclopenthiazide. The risk or severity of adverse effects can be increased when Methohexital is combined with Gepirone. The metabolism of Palonosetron can be decreased when combined with Diltiazem. The risk or severity of adverse effects can be increased when Betamethasone is combined with Nalidixic Acid. The risk or severity of adverse effects can be increased when Candoxatril is combined with Nimesulide. The risk or severity of adverse effects can be increased when Olmesartan is combined with Nesiritide. The serum concentration of Cyclosporine can be increased when it is combined with Alogliptin. Tinoridine may decrease the antihypertensive activities of Betaxolol. The risk or severity of adverse effects can be increased when Thymol is combined with Lercanidipine. The therapeutic efficacy of Methallenestril can be decreased when used in combination with Secobarbital. The metabolism of Tacrolimus can be decreased when combined with Lisinopril. The risk or severity of adverse effects can be increased when Carbaspirin calcium is combined with Hydrocortisone. The risk or severity of adverse effects can be increased when Timolol is combined with Papaverine. Masoprocol may increase the neuroexcitatory activities of Levofloxacin. Iproniazid may increase the hypotensive activities of Indapamide. The metabolism of Methohexital can be increased when combined with Rifabutin. Pargyline may increase the hypertensive activities of Tetryzoline. The risk or severity of adverse effects can be increased when Amobarbital is combined with Difenoxin. Trimethoprim may increase the QTc-prolonging activities of Iloperidone. The therapeutic efficacy of Tafluprost can be decreased when used in combination with Benzydamine. The risk or severity of adverse effects can be increased when Prednisolone is combined with Hepatitis B Vaccine (Recombinant). Dihydralazine may increase the hypotensive activities of Cafedrine. The risk or severity of adverse effects can be increased when Salicylamide is combined with Dexamethasone. The risk or severity of adverse effects can be increased when Sitagliptin is combined with Enalapril. Secobarbital may increase the hypotensive activities of Terazosin. Azelastine may increase the sedative activities of Rotigotine. The metabolism of Diclofenac can be decreased when combined with Clarithromycin. The metabolism of Atorvastatin can be decreased when combined with Pioglitazone. Ipratropium bromide may increase the anticholinergic activities of Glycopyrronium. The serum concentration of Dienestrol can be decreased when it is combined with Letaxaban. The risk or severity of adverse effects can be increased when Dyclonine is combined with Flunarizine. The metabolism of Estrone sulfate can be increased when combined with Pentobarbital. The risk or severity of adverse effects can be increased when Enalapril is combined with Floctafenine. The serum concentration of Verapamil can be decreased when it is combined with Efavirenz. The metabolism of Beraprost can be decreased when combined with Trimethoprim. The metabolism of Captopril can be decreased when combined with Terbinafine. The serum concentration of Vincristine can be increased when it is combined with Mefloquine. The risk or severity of adverse effects can be increased when Hexobarbital is combined with Ecgonine. Nimesulide may increase the anticoagulant activities of Protocatechualdehyde. The risk or severity of adverse effects can be increased when Floctafenine is combined with Salicylic acid. The metabolism of Dronedarone can be decreased when combined with Cimetidine. The metabolism of Dapagliflozin can be increased when combined with Secobarbital. Bimatoprost may increase the hypotensive activities of Candesartan. The metabolism of Bupropion can be decreased when combined with Olaparib. The risk or severity of adverse effects can be increased when Naftifine is combined with Alendronic acid. The risk or severity of adverse effects can be increased when Clonidine is combined with Maprotiline. The metabolism of Cinnarizine can be decreased when combined with Losartan. The risk or severity of adverse effects can be increased when Bifonazole is combined with Fendiline. The risk or severity of adverse effects can be increased when Sulfasalazine is combined with Tixocortol. The serum concentration of Cholecalciferol can be increased when it is combined with Fusidic Acid. The risk or severity of adverse effects can be increased when Nadolol is combined with Nesiritide. Ergoloid mesylate may increase the hypertensive activities of Synephrine. Losartan may increase the hypotensive activities of Unoprostone. Bupranolol may increase the hypotensive activities of Cyclopenthiazide. The therapeutic efficacy of Iobenguane can be decreased when used in combination with Nylidrin. The risk or severity of adverse effects can be increased when Oxyphenonium is combined with Solifenacin. Flunisolide may increase the fluid retaining activities of Stanozolol. The risk or severity of adverse effects can be increased when Umeclidinium is combined with Topiramate. The serum concentration of Alogliptin can be decreased when it is combined with Boceprevir. Dextroamphetamine may increase the analgesic activities of Fentanyl. The therapeutic efficacy of Picosulfuric acid can be decreased when used in combination with Daptomycin. The risk or severity of adverse effects can be increased when Heroin is combined with Polythiazide. The serum concentration of Spectinomycin can be increased when it is combined with Tenofovir disoproxil. The metabolism of Losartan can be decreased when combined with Chloroxine. The serum concentration of Bosutinib can be increased when it is combined with Quinidine. The serum concentration of Diclofenac can be decreased when it is combined with Primidone. The serum concentration of Bupranolol can be decreased when it is combined with Secobarbital. The therapeutic efficacy of Picosulfuric acid can be decreased when used in combination with Mezlocillin. Solifenacin may increase the QTc-prolonging activities of Lenvatinib. The metabolism of Montelukast can be decreased when combined with Pyrimethamine. The therapeutic efficacy of Insulin Lispro can be decreased when used in combination with Hydrochlorothiazide. The serum concentration of Cerivastatin can be increased when it is combined with Ergotamine. Clobetasone may increase the fluid retaining activities of Methyltestosterone. The risk or severity of adverse effects can be increased when Reserpine is combined with Amlodipine. The metabolism of Rotigotine can be decreased when combined with Sulfisoxazole. Thiopental may increase the hypotensive activities of Bisoprolol. The risk of a hypersensitivity reaction to Allopurinol is increased when it is combined with Polythiazide. The therapeutic efficacy of Hydrochlorothiazide can be decreased when used in combination with Masoprocol. The therapeutic efficacy of Polythiazide can be decreased when used in combination with Pirfenidone. The serum concentration of Eliglustat can be increased when it is combined with Cyclosporine. The risk or severity of adverse effects can be increased when Lysergic Acid Diethylamide is combined with Ivacaftor. Neostigmine may increase the bradycardic activities of Penbutolol. Phenoxypropazine may increase the hypotensive activities of Ramipril. The risk or severity of adverse effects can be increased when Benzatropine is combined with Atropine. The risk or severity of adverse effects can be increased when Benzocaine is combined with Desipramine. The serum concentration of Digoxin can be increased when it is combined with Zofenopril. The metabolism of Pimecrolimus can be decreased when combined with Dihydroergotamine. The risk or severity of adverse effects can be increased when Ergonovine is combined with Ethanol. The metabolism of Tipranavir can be decreased when combined with Terbinafine. The risk or severity of adverse effects can be increased when Fluprednidene is combined with Pazufloxacin. Yohimbine may decrease the antihypertensive activities of Perindopril. Lercanidipine may increase the hypotensive activities of Selexipag. The risk or severity of adverse effects can be increased when Morniflumate is combined with Ketorolac. Furazolidone may increase the hypotensive activities of Penbutolol. The serum concentration of Epirubicin can be decreased when it is combined with Nafcillin. Felodipine may increase the hypotensive activities of Manidipine. The risk or severity of adverse effects can be increased when Amisulpride is combined with Chlorzoxazone. The risk or severity of adverse effects can be increased when Etorphine is combined with Pramocaine. The risk or severity of adverse effects can be increased when Estrone is combined with Tecemotide. The metabolism of Licofelone can be increased when combined with Secobarbital. The risk or severity of adverse effects can be increased when Scopolamine is combined with Nefazodone. The metabolism of Sotalol can be decreased when combined with Amodiaquine. Perindopril may increase the hypotensive activities of Cyclopenthiazide. The serum concentration of Neratinib can be increased when it is combined with Fusidic Acid. Dapoxetine may increase the orthostatic hypotensive activities of Lisinopril. The risk or severity of adverse effects can be increased when Propantheline is combined with Methscopolamine. The risk or severity of adverse effects can be increased when Spironolactone is combined with Indapamide. Pentobarbital may increase the hypotensive activities of Sodium Nitrite. The metabolism of Bexarotene can be decreased when combined with Irbesartan. The serum concentration of Buprenorphine can be increased when it is combined with Ombitasvir. The metabolism of Dasabuvir can be decreased when combined with Fluvoxamine. The metabolism of Brinzolamide can be decreased when combined with Olaparib. The risk or severity of adverse effects can be increased when Aclidinium is combined with Ketobemidone. The risk or severity of adverse effects can be increased when Temazepam is combined with Amobarbital. The metabolism of Dasabuvir can be decreased when combined with Manidipine. The risk or severity of adverse effects can be increased when Olmesartan is combined with Nisoldipine. Amobarbital may increase the hypotensive activities of Papaverine. Colesevelam can cause a decrease in the absorption of Tolmetin resulting in a reduced serum concentration and potentially a decrease in efficacy. The risk or severity of adverse effects can be increased when Pentobarbital is combined with Amobarbital. The serum concentration of Ritonavir can be increased when it is combined with Cobicistat. The risk or severity of adverse effects can be increased when Dihydromorphine is combined with Carisoprodol. The therapeutic efficacy of Glyburide can be decreased when used in combination with Estradiol. The serum concentration of Simvastatin can be increased when it is combined with Fluconazole. Formoterol may increase the QTc-prolonging activities of Chloroquine. The metabolism of Sertraline can be decreased when combined with Ritonavir. The therapeutic efficacy of Felodipine can be decreased when used in combination with Sarilumab. The metabolism of Morphine can be decreased when combined with Cyclosporine. The metabolism of Methoxsalen can be decreased when combined with Cobicistat.